Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 2/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | RIPK2 | O43353 | 11/20 | 0.49 |
| ▸ | SRC | P12931 | 3/20 | 0.48 |
| ▸ | KDR | P35968 | 2/20 | 0.47 |
| ▸ | KIT | P10721 | 1/20 | 0.47 |
| ▸ | FLT3 | P36888 | 1/20 | 0.47 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.44 |
| ▸ | IKBKB | O14920 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.43 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5623732 | 0.87 | RIPK2 (0.49) | RIPK2SRCKDRLCKTGFBR1 | |
| SCHEMBL4257241 | 0.84 | RIPK2 (0.55) | CA12CA1CA2CA9RIPK2 | |
| SCHEMBL4263207 | 0.83 | RIPK2 (0.56) | RIPK2SRCKDRKITFLT3 | |
| SCHEMBL4260583 | 0.82 | KDR (0.55) | RIPK1RIPK2SRCKDRKIT | |
| SCHEMBL4258858 | 0.82 | RET (0.55) | RIPK1CA12CA1CA2CA9 | |
| SCHEMBL4265907 | 0.81 | RIPK2 (0.61) | RIPK2SRCKDRLCKTGFBR1 | |
| SCHEMBL4255820 | 0.80 | KDR (0.54) | RIPK2SRCKDRLCKTGFBR1 | |
| SCHEMBL4265352 | 0.80 | RIPK2 (0.61) | RIPK2SRCKDRLCKTGFBR1 | |
| SCHEMBL4262663 | 0.79 | RIPK2 (0.58) | RIPK1RIPK2SRCKDRCSNK1E | |
| SCHEMBL4261925 | 0.79 | RIPK2 (0.69) | RIPK2SRCKDRFLT3LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7307097-B2 | Chemical compounds | SMITHKLINE BEECHMAN CORPORATION (US) | 2007-12-11 | — | — | US | disclosed |
| US-20040198986-A1 | 5-amino-1,3-substituted pyrazole-4-carboxylic acid amides of given formula, such as 5-Amino-1-tert-butyl-3-{4-[3-(2-fluoro-5-trifluoromethyl-phenyl)-ureido]-phenyl}-1H-pyrazole-4-carboxylic acid amide; treating cancer; receptor tyrosine kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2004-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198986-A1 | 5-amino-1,3-substituted pyrazole-4-carboxylic acid amides of given formula, such as 5-Amino-1-tert-butyl-3-{4-[3-(2-fluoro-5-trifluoromethyl-phenyl)-ureido]-phenyl}-1H-pyrazole-4-carboxylic acid amide; treating cancer; receptor tyrosine kinase inhibitors | ERBB2, RET, ERBB4 | RIPK1 1256/4885CA12 4504/4885CA1 4069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.